---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Cost-effectiveness evidence"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Cost-effectiveness evidence. Topics: ICER assessment of synthetic psilocybin: announcement and timeline; ICER planned cost-effectiveness analysis; ICER planned budget impact analysis; Published cost-effectiveness analysis: United States, psilocybin-assisted therapy as third-line treatment; 10 further topics. 15 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics/cost-effectiveness"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

No source in this report presents a cost-effectiveness or budget impact model of COMP360 itself, and none quotes a price for it. ICER is assessing synthetic psilocybin against esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation, with a model analysis plan due January 22, 2027, a five-year health care system cost-effectiveness model, and a separate five-year budget impact analysis; its final evidence report is scheduled for 06/21/2027. Published analyses of psilocybin therapy report $117,517 per QALY gained over 12 months from a limited healthcare perspective, cost savings of approximately $7000 per patient compared with standard of care, and cost-effectiveness when the cost of therapist support was reduced by 50% and the psilocybin price to £400 to £800 per person. For the comparator, ICER's 2019 report estimated approximately $198,000 per QALY gained for esketamine. The company plans drug reimbursement through the pharmacy benefit and monitoring through CPT Category III codes, and presented health economics posters on real-world costs across TRD health states at Psych Congress 2026. A payer panel noted that the effect of psilocybin on later treatment needs leaves “an uncertain impact to the total cost of care.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/); [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/); [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/); [McCrone et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755218/); [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Psych Congress release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Debut-U-S--HCP-Education-Campaign-and-Present-New-HEOR-Data-at-Psych-Congress-2026/default.aspx); [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-4.1-2"></a>

### ICER assessment of synthetic psilocybin: announcement and timeline

> “The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of synthetic psilocybin (COMPASS Pathways) for treatment-resistant depression.”
> “Following the public comment period, a revised scoping document will be posted on or about November 18, 2026.”

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-therapy-for-treatment-resistant-depression/)

> “11/18/2026 Revised Scoping Document”
> “01/22/2027 Model Analysis Plan”
> “03/16/2027 Draft Evidence Report”
> “05/20/2027 Evidence Presentation”
> “06/21/2027 Final Evidence Report and Meeting Summary”

Source: [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/)

<a id="topic-4.1-3"></a>

### ICER planned cost-effectiveness analysis

> “A detailed economic model analysis plan with proposed methodology, model structure, model parameters, model inputs, and model assumptions will be published on January 22, 2027.”
> “The base-case analysis will use a five-year time horizon, reflecting uncertainty in the durability of treatment effects and the limited evidence available to support longer-term extrapolation.”
> “The base case analysis will take a health care system perspective (i.e., focus on direct medical care costs only).”
> “The model is expected to capture treatment response, remission, non-response, relapse, and subsequent treatment given available data to populate and transition between states.”
> “Treatment effectiveness will be estimated using a network meta-analysis.”
> “Relevant pairwise comparisons will be made between treatments, and results will be expressed in terms of the marginal cost per QALY gained, cost per evLY gained, cost per life-year gained, and cost per case of remission gained.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-4.1-4"></a>

### ICER planned budget impact analysis

> “In separate analyses, we will explore the potential health care system budgetary impact of treatment over a five-year time horizon, utilizing published or otherwise publicly-available information on the potential population eligible for treatment and results from the economic model for treatment costs and cost offsets.”
> “This budgetary impact analysis will indicate the relation between treatment prices and level of use for a given potential budget impact, and will allow assessment of any need for managing the cost of such interventions.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-4.1-5"></a>

### Published cost-effectiveness analysis: United States, psilocybin-assisted therapy as third-line treatment

> “We assumed the total cost of PAT was $5000, which we varied in sensitivity analyses ($3000–20,000).”
> “PAT leads to an additional 0.031 QALYs and $3639 costs compared to SOC over 12 months, giving an ICER of $117,517 per QALY gained from a limited healthcare perspective.”
> “Using a $150,000 cost-effectiveness threshold, PAT had a 75% probability of being the cost-effective choice, and it was associated with a lower expected loss than SOC ($301 vs. $1307).”
> “PAT had a 1% probability of being cost-effective when its overall costs were $10,000 and 95% when its costs were $3000.”

Source: [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/)

<a id="topic-4.1-6"></a>

### Published cost-effectiveness analysis: United States Markov model with a 6-week cycle

> “Compared with the standard of care, PAT was more effective and less costly, yielding approximately $7000 in cost savings and a gain of 0.10 QALYs per patient.”
> “Extending the horizon to 30 years in scenario analyses increased cumulative savings to $215 900 with gains of 9.87 QALYs.”

Source: [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/)

<a id="topic-4.1-7"></a>

### Published cost-effectiveness analysis: United Kingdom, 6-month decision model

> “The expected healthcare cost of PAP varied from £6132 to £7652 depending on the price of psilocybin.”
> “QALYs were highest for psilocybin (0.310), followed by CBT alone (0.283), conventional medication alone (0.278), and their combination (0.287).”
> “Psilocybin was shown to be cost-effective compared to the other therapies when the cost of therapist support was reduced by 50% and the psilocybin price was reduced from its initial value to £400 to £800 per person.”

Source: [McCrone et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755218/)

<a id="topic-4.1-8"></a>

### Clinician costs with group compared with individual monitoring

> “Group therapy saved 50.9% of clinician costs for MDMA-PTSD and 34.7% for psilocybin-MDD, or $3,467 and $981 per patient, respectively.”

Source: [Marseille et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10731307/)

<a id="topic-4.1-9"></a>

### Comparator context: ICER 2019 evaluation of esketamine

> “We thus applied its WAC price ($295 per 28 mg device) for our analyses.”
> “This resulted in incremental cost effectiveness ratios of approximately $198,000 per QALY gained and approximately $2.6 million per LY gained.”

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

| Measure | Esketamine |
| --- | --- |
| Annual average WAC | “$32,400” |
| Annual price to achieve $100,000 per QALY | “$17,700” |
| Annual price to achieve $150,000 per QALY | “$25,200” |
| Discount from WAC required to reach thresholds | “25-52%” |

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

<a id="topic-4.1-10"></a>

### Comparator context: published United States cost-effectiveness analysis of esketamine

> “Base case ICERs were $237,111/QALY (societal) and $242,496/QALY (healthcare sector).”
> “At a cost-effectiveness threshold of $150,000/QALY, esketamine’s value-based price was approximately $140/dose (versus a current price of $240/dose).”

Source: [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/)

<a id="topic-4.1-11"></a>

### Company statements on pricing and value

> “If you take a look at the dynamics of pricing and how that works, it is not necessarily the pricing, a premium that is applied, it is the value that these products are bringing to the healthcare system.”
> “Payers respond very well to a product that has proven efficacy in that patient population.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Nath said Spravato provides a reference point but declined to commit to a specific pricing benchmark.”

Source: [Keshavan (2026)](https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/)

<a id="topic-4.1-12"></a>

### Company reimbursement model: drug through the pharmacy benefit, monitoring through the medical benefit

> “COMP360 expected to be available through specialty pharmacy and buy-and-bill”
> “Coding and reimbursement for COMP360 have not yet been established and are subject to change from current thinking”
> “CPT III codes accepted, and language released by AMA for Psychedelic Drug Monitoring Services; published in the CPT Manual and effective on January 1, 2024”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 will be available through both specialty pharmacy and buy-and-bill, with drug reimbursed through pharmacy benefit.”
> “Ultimately, we anticipate that taking 12-18 months.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “therapies that use psilocybin or psilocin are currently precluded from reimbursement in the United States.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-4.1-13"></a>

### Company market sizing

> “Today, for the estimated 4 million individuals in the U.S. who are impacted by treatment-resistant depression, there is only one approved and marketed drug with that indication, and fewer than 3% of those patients are actually being treated with it.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-4.1-14"></a>

### Payer panel: cost and total cost of care concerns

> “Additionally, payer participants are concerned with the cost-effectiveness of potentially requiring multiple health professionals at specialized centers to provide psilocybin administration and observation.”
> “Additionally, payer participants emphasized that the unknown impact of psilocybin on ongoing treatment needs results in an uncertain impact to the total cost of care.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-4.1-15"></a>

### Company health economics and outcomes research posters at Psych Congress 2026

> “Real-World Healthcare Costs and Resource Utilization Across Health States Among Patients with Treatment-Resistant Depression – presented by Yechu Hua, poster #186”
> “Characterization of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression – presented by Vicki Wing, poster #88”

Source: [COMPASS Pathways Psych Congress release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Debut-U-S--HCP-Education-Campaign-and-Present-New-HEOR-Data-at-Psych-Congress-2026/default.aspx)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
